About Suven Life Sciences Limited

Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutics for neurodegenerative disorders, especially dementia and central nervous system (CNS) indications with high unmet needs and growing patient populations. Incorporated in 1989 and founded by the Jasti Family, the company is based in Hyderabad and listed on BSE and the National Stock Exchange of India Limited. It operates primarily as an R&D-led organization, discovering and developing drugs targeting CNS diseases.

Suven’s pipeline consists of 13 molecules with 5 in clinical trials, among which 3 are in advanced Phase 2 and Phase 3 stages. Lead drugs include Masupirdine (SUVN‑502), Samelisant (SUVN‑G3031), Ropanicant (SUVN‑911), Usmarapride (SUVN‑D4010), and SUVN‑I6107, which address cognitive disorders, schizophrenia, Alzheimer’s disease, sleep-wake disorders, and depressive disorders. The company holds over 2,850 global patents extending up to 2035 and beyond, underscoring a significant intellectual property portfolio.

Suven Life Sciences has geographic coverage across India, the USA, Europe, and other global markets. It operates two research centers in Telangana: IDA Jeedimetla, Hyderabad, and IDA Pashamylaram, Sangareddy, supported by a team of 132 employees, including 102 research scientists.

Suven Life Sciences Limited Business Segment and Geographic Presence 

Suven’s business operates as a single reportable segment centered on R&D and drug development in CNS disorders. Its geographic revenue reporting spans India, the United States, Europe, and other parts of the world.

The company focuses on discovery-led R&D, development, and commercialization of targeted therapeutics for neurodegenerative and CNS diseases. In addition, it provides contract research and manufacturing services (CRAMS) to global pharmaceutical and biotech companies.

Suven Life Sciences Limited Key Management

• Venkateswarlu Jasti – Chairman & Managing Director
• Smt. Sudharani Jasti – Whole-time Director
• Dr. N.V.S. Ramakrishna – President & Chief Scientific Officer
• M. Mohan Kumar – Chief Financial Officer
• Shrenik Soni – Company Secretary

Latest Updates on Suven Life Sciences Limited

• Raised Rs 857 crore through issuance of 6.4 crore convertible warrants on a preferential basis in FY 2024-25, with full subscription reflecting strong investor confidence.
• Granted 128 global product patents during the year, bolstering protection for key compounds in clinical development and potential future launch.
• Spent Rs 203.87 crore on consolidated R&D and invested in expanding research infrastructure.
• Maintained a research-first team of 132 professionals including 102 scientists across its Telangana research centers.
• Issued 5,54,500 stock options under ESOP-2020 as of March 31, 2025, aligning managerial incentives with long-term value creation.
• Invested US$94.74 million as of June 2025 in its US clinical development platform to advance late-stage asset development.